Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 233

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

Open access
Zhou, Caicun, Solomon, Benjamin, Loong, Herbert H., Park, Keunchil, Pérol, Maurice, Arriola, Edurne, Novello, Silvia, Han, Baohui, Zhou, Jianying, Ardizzoni, Andrea, Mak, M. Perez, Santini, Fernando C., Elamin, Yasir Y., Drilon, Alexander, Wolf, Jürgen, Payakachat, Nalin, Uh, Minji K., Rajakumar, Deborah, Han, Hongmei, Puri, Tarun, Soldatenkova, Victoria, Lin, A. Bence, Lin, Boris K., Goto, Koichi · 2023 · New England Journal of Medicine

Abstract

BACKGROUND: fusion-positive non-small-cell lung cancer (NSCLC) in a nonrandomized phase 1-2 study. METHODS: In a randomized phase 3 trial, we evaluated the efficacy and safety of first-line selpercatinib as compared with control treatment that consisted of platinum-based chemotherapy with or without pembrolizumab at the investigator's discretion. The primary end point was progression-free survival assessed by blinded independent central review in both the intention-to-treat-pembrolizumab population (i.e., patients whose physicians had planned to treat them with pembrolizumab in the event that they were assigned to the control group) and the overall intention-to-treat population. Crossover from the control group to the selpercatinib group was allowed if disease progression as assessed by blinded independent central review occurred during receipt of control treatment. RESULTS: In total, 212 patients underwent randomization in the intention-to-treat-pembrolizumab population. At the time of the preplanned interim efficacy analysis, median progression-free survival was 24.8 months (95% confidence interval [CI], 16.9 to not estimable) with selpercatinib and 11.2 months (95% CI, 8.8 to 16.8) with control treatment (hazard ratio for progression or death, 0.46; 95% CI, 0.31 to 0.70; P<0.001). The percentage of patients with an objective response was 84% (95% CI, 76 to 90) with selpercatinib and 65% (95% CI, 54 to 75) with control treatment. The cause-specific hazard ratio for the time to progression affecting the central nervous system was 0.28 (95% CI, 0.12 to 0.68). Efficacy results in the overall intention-to-treat population (261 patients) were similar to those in the intention-to-treat-pembrolizumab population. The adverse events that occurred with selpercatinib and control treatment were consistent with those previously reported. CONCLUSIONS: fusion-positive NSCLC. (Funded by Eli Lilly and others; ClinicalTrials.gov number, NCT04194944.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2309457

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 233

Metadata

Authors
Zhou, C., Solomon, B., Loong, H. H., Park, K., Pérol, M., Arriola, E., Novello, S., Han, B., Zhou, J., Ardizzoni, A., Mak, M. P., Santini, F. C., Elamin, Y. Y., Drilon, A., Wolf, J., Payakachat, N., Uh, M. K., Rajakumar, D., Han, H., Puri, T., Soldatenkova, V., Lin, A. B., Lin, B. K., & Goto, K.
Venue
New England Journal of Medicine
Published
2023-11-16
Volume
389
Issue
20
Pages
1839-1850
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4387844786
Cited by
233
References
2
FWCI
37.01
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC. https://app.cochat.ai/papers/10.1056/nejmoa2309457
The paper
Zhou, C., Solomon, B., Loong, H. H., Park, K., Pérol, M., Arriola, E., Novello, S., Han, B., Zhou, J., Ardizzoni, A., Mak, M. P., Santini, F. C., Elamin, Y. Y., Drilon, A., Wolf, J., Payakachat, N., Uh, M. K., Rajakumar, D., Han, H., . . . Goto, K. (2023). First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2309457

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.